Xbrane Biopharma: Target date for potential US approval set - Redeye

The FDA has accepted Xbrane's BLA resubmission for Lucamzi and set a BsUFA action date of 29 October 2026, keeping potential US approval on track for year-end and representing a key, but binary, catalyst for the investment case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1171048/xbrane-biopharma-target-date-for-potential-us-approval-set?utm_source=finwire&utm_medium=RSS